

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



廣州白雲山醫葯集團股份有限公司

**GUANGZHOU BAIYUNSHAN PHARMACEUTICAL HOLDINGS CO., LTD.**

*(a joint stock company with limited liability established in the People's Republic of China)*

(H Share Stock Code: 0874)

## **VOLUNTARY ANNOUNCEMENT**

This is a voluntary announcement made by Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited (the “Company”).

Reference is made to the announcements of the Company dated 31 July 2014 and 22 August 2014 in relation to the progress on the production approval documents of “Sildenafil Citrate” for the product of the Company named “Jin Ge”.

The Company received the drug approval documents in respect of the supplemental application issued by the Administrative Processing Center of the China Food and Drug Administration in respect of “Sildenafil Citrate” and “Sildenafil Citrate tablets”. The production registration approval application documents of “Sildenafil Citrate” active pharmaceutical ingredients and “Sildenafil Citrate” tablets submitted by the Company were approved by the Administrative Processing Center of the China Food and Drug Administration, the numbers of the drug approval documents were “Guo Yao Zhun Zi H20143277” and “Guo Yao Zhun Zi H20143255” respectively.

The Company will carry out the relevant works as soon as possible so that the production and launching of the Baiyunshan “Jin Ge” can be achieved as early as possible.

The Company wishes to inform the investors that the Company’s designated media for publication of its information include Shanghai Securities News (上海證券報), Securities Times (證券時報), China Securities Journal (中國證券報), Securities Daily (證券日報), the website of the Shanghai Stock Exchange (<http://www.sse.com.cn>) and the website of The Stock Exchange of Hong Kong Limited (<http://www.hkex.com.hk>). Investors are advised to take due care in investment and be aware of the relevant risks.

The Board of

**Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited**

Guangzhou, the PRC, 2 September 2014

*As at the date of this announcement, the Board comprises Mr. Li Chuyuan, Mr. Chen Mao, Ms. Liu Juyan, Ms. Cheng Ning, Mr. Ni Yidong, Mr. Wu Changhai and Mr. Wang Wenchu as executive directors, and Mr. Wong Lung Tak Patrick, Mr. Qiu Hongzhong, Mr. Fang Shuting and Mr. Chu Xiaoping as independent non-executive directors.*